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Summary Cisplatinum may prove to be a valuable agent for the elimination of diseased cells in the bone
marrow of patients with neuroblastoma. In this study, we measured the efficacy of cisplatinum on human
neuroblastoma cell lines and on normal human bone marrow progenitors, GM-CFC and CFU-F. Data
indicate that the therapeutic index of cisplatinum is high. We set up an experimental model consisting of a
mixture of human bone marrow and human neuroblastoma cells in order to confirm these preliminary results
in purging conditions. Results indicate that cisplatinum exhibits a high and specific tumoricidal property and
appears to be valid in bone marrow purging.
The relationship between drug-dose and therapeutic efficacy
in the treatment of neuroblastoma (NB) has led to the use of
high-dose chemotherapy with autologus bone marrow trans-
plantation (ABMT) (Hartmann el al., 1985; Laporte et al.,
1987). The therapeutic benefits of ABMT in the treatment of
NB are offset by the possible reinjection of malignant cells in
the patient because NB very frequently exhibit bone marrow
involvement. Even when the marrow is collected in complete
remission, the risk of contamination due to the presence of
residual disease cannot be excluded (Bayle et al., 1985).
Various purging techniques have therefore been tested:
biological separation (Reisner & Gan, 1985), immunological
procedures using monoclonal antibodies with complement
(Saarinen et al., 1985) or conjugated with a toxin (Raso et
al., 1982) or with magnetic beads (Trealeaven et al., 1984).
Chemical agents have also been employed in purging proce-
dures. Asta-Z is an active metabolite of cyclophosphamide
which has been shown to cure myelogenous leukemia (Shar-
kis et al., 1980). It is now routinely used to purge human NB
bone marrows before ABMT. Unfortunately bone marrow
purging by Asta-Z frequently induces a delay of 7-10 days
in the patient's haematological reconstitution (Beaujean et
al., 1987). This adverse effect led us to study a compound
exhibiting less myelotoxicity. Our choice focused on cis-
platinum, given its moderate myelotoxicity.
Five previous studies concerning cisplatinum (CDDP) have
been published. Three of them (Ajani et al., 1986; Ogawa et
al., 1975; Umbach et al., 1984) only dealt with the human
haematopoietic toxicity of CDDP. The other two were
screening studies of its tumoricidal activity (Ajani et al.,
1985; Umbach et al., 1985). No publication has yet described
the effect of CDDP on tumour cells and haematopoietic
progenitors in routine ABMT purging conditions. We
therefore decided to set up an experimental model consisting
of a mixture of human neuroblastoma cells in order to
evaluate the efficacy of CDDP in purging conditions, but this
was preceded by a preliminary experiment which was devoted
to the evaluation of CDDP efficacy on NB cell lines alone.
The mixture which contained a NB tumour cell line (IGR-N-
835) and normal human bone marrow cells at a ratio of 10%
was treated with a drug concentration which ranged from 0
to 10 IiM. A larger range of concentration was then applied
to bone marrow progenitor cells: granulocyte-macrophage
colony forming cells (GM-CFC) and fibroblast precursor
cells (CFU-F).
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Materials and methods
Chemicals and media
Cisplatinum (CDDP, MW = 300) was provided by the
Laboratoires Roger Bellon (Neuilly/Seine, France). Just
before use, the drug was dissolved in sterile saline. For the
culture of bone marrow and tumour cell mixtures, MEM-
HITES medium was used (Carney et al., 1981). This defined
medium consists of products dissolved in MEM medium at
the following final concentrations: 10-8M hydrocortisone,
5 .g ml-' insulin, 100 I g ml-' human transferrin, 10-8M
17 P-oestradiol, 3 x Io-' M sodium selenite.
Human cell materials
Human neuroblastoma cell lines. Two human
neuroblastoma cell lines, SK-N-SH and SK-N-AS, were
kindly provided by Dr Helson (Sloan Kettering Institute,
New York). The third one, IGR-N-835, was originated in
our laboratory and derived from an undifferentiated
immature NB of a 2-year-old patient who had undergone
intensive chemotherapy treatment (four cycles of
cyclophosphamide, doxorubicine and vincristine) and
exhibited tumour progression. The IGR-N-835 cells were
transferred only 15 times for the experiments conducted for
the purposes of the present study.
All lines were cultured at 37°C in 25 cm2 flasks containing
MEM-10% heat inactivated fetal calf serum (HIFCS) in an
incubator with 7.5% carbon dioxide. The media were
changed twice a week. SK-N-SH and SK-N-AS lines were
dissociated with 0.25% trypsin-EDTA and the IGR-N-835
cell line with 0.05% trypsin-EDTA, until high cell density
was achieved.
Normal bone marrow. Heparinised normal bone marrow
samples were obtained from 10 healthy donors after
informed consent. The bone marrow cells were separated on
a Hypaque-Ficoll gradient. The mononuclear cells were
washed twice in a buffered alpha medium and then
resuspended at a concentration of 107 cells ml-' in a medium
buffered by HEPES.
Measurements ofCDDP cytotoxicity to NB cell lines
Clonogenic monolayer assays (CMA) were performed.
Briefly, 3 x 105 cells of SK-N-SH and SK-N-AS and 9 x 105
cells of IGR-N-835 were seeded in 60 mm culture grade Petri
dishes (Nunc) and cultured in MEM-10% HIFCS. Once the
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exponential phase of growth was reached, viable cells were
counted with Trypan blue in three replicate dishes so that the
number ofcells could be determined as a function of the dose
ofCDDP. This medium was then replaced using fresh MEM-
HITES with 2% HIFCS, and CDDP ranging from 0 to
10gM was added for 1 h at 37C, 7.5% CO2. After this drug
treatment, the cells were trypsinised and cultured in MEM-
10% HIFCS in 60mm culture grade Petri dishes for a fur-
ther 12 days for SK-N-SH and SK-N-AS and a further 21
days for IGR-N-835. Anchored colonies were fixed by
methanol and stained with violet crystal. Colonies of more
than 50 cells were counted using an image analyser Magiscan
II (Joyce Loebel Co.) according to a previously described
programme (Kahn et al., 1986). The percentage of surviving
colonies was then estimated and plotted as a function of drug
concentration in order to determine the IC50 and IC90 values
(drug concentration leading to the formation of 50% and
10% of the number of colonies found for untreated cells,
respectively).
Measurements ofCDDP cytotoxicity to bone marrow
progenitor cells
CDDP was immediately diluted, and introduced into a
mononuclear bone marrow cell suspension in 2% HIFCS to
a final concentration ranging from 10 to 150 gM for 1 h at
37°C. In order to avoid any thermic artefact (Ogawa et al.,
1975), the drug was introduced into the cell samples after
10min incubation. The pH ranged from 7.20 at the begin-
ning to 7.26 at the end of the experiment.
Two types of culture were performed with these incubated
cells. (1) GM-CFC: bone marrow cells were cultured for 14
days in methylcellulose with placental colony stimulating
factor (CSF) as previously described. Colonies of up to 50
cells were scored under an inverted microscope. (2) CFU-F
were cultured in duplicate using a technique comparable to
that described by Siena et al. (1985). Medullary cells (106)
were plotted in 35 mm culture dishes containing 2 ml of
medium, 8% CSF-culture medium was changed on day 3 and
CFU-F colonies of up to 50 cells were scored after staining
by May-Grunwald Giemsa. For both GM-CFC and CFU-F,
the results were compared with the controls cultured under
the same conditions.
Measurements of CDDP toxicity to mixtures
The term mixture refers to a suspension composed of
mononuclear bone marrow cells and IGR-N-835 cells. The
bone marrow cells were mixed with previously trypsinised
IGR-N-835 cells at 10% and 1% ratios. The final mixture
(107 bone marrow cells ml-') was cultured in MEM-HITES
with 2% HIFCS. These mixtures were then observed at
various times, in order to monitor the proliferation of
tumour cells.
Mixtures were treated for 1 h using the same procedure as
that used for NB cell lines or bone marrow cells alone. The
mixture was then washed and plated for two independent
cultures, where focus was put on tumour cells in the mixture
on one hand and on bone marrow progenitor cells on the
other hand, as indicated above. CDDP efficiency on tumour
cells was determined using a CMA at 21 days and at 50 days.
For each drug concentration (0-10 JAM for NB cell lines and
0-150 JAM for bone marrow cells), colonies of up to 50 cells
were then counted in triplicate under an inverted microscope
and the results were expressed in terms of Ic90 and IC90
values.
Statistical methods
IC50 and IC90 values were graphically estimated for the three
NB cell lines (SK-N-SH, SK-N-AS, IGR-N-835), as well for
GM-CFC and CFU-F. Regression analysis was used in order
to fit the proportion of surviving cells as a function of drug
concentration in the IGR-N-835-bone marrow cell mixture,
GM-CFC and CFU-F. We applied two types of
dose-response models, a linear and an exponential one.
Results
IC50 and IC90 values from the three NB cell lines (SK-N-SH,
SK-N-AS and IGR-N-835) cultured in a CMA assay were
graphically obtained. Values were found to be similar and
ranged from 0.4 to 0.8 JAM for IC50 and from 1 to 7.5 JAM for
IC90 (Table I).
Figure 1 shows the number of remaining colonies of IGR-
N-835 cells cultured with normal human bone marrow cells
as a function of the CDDP concentration. CDDP produced a
total tumoricidal effect at 10 gAM. The fit of the data observed
with the exponential dose-response model was very satisfac-
tory and the linear model was obviously inadequate. The IC50
and IC90 values were equal to 1.29 gAM (95% CI:
1.14-1.47IAM) and 4.2J1M (95% CI: 3.5-4.9JAM) respec-
tively, as shown in Table I. Given the results obtained con-
cerning NB cells in the mixture, we tried to fit those obtained
for GM-CFC and CFU-F cells (Figures 2 and 3), in a range
of a concentration below 1OgM which only covers the first
decrease in survival of these cells. For both progenitor cells,
the IC50 and IC90 value estimations obtained with the linear
and the exponential dose-response models were similar
(Table I). Our estimations can be defined as an average of
the values of the two models: the IC50 value was 70 JAM for
GM-CFC and 367 JAM for CFU-F while the IC90 value was
157.5 JAM for the GM-CFC and 906.5 jaM for the CFU-F.
Table II indicates the estimated remaining surviving cell pro-
portions of GM-CFC and CFU-F in the mixture, as a func-
tion of the CDDP concentration. In Table II lower and
higher values of the 95% confidence intervals of the
estimated remaining proportion of cells are based, respec-
tively, on the lower and the higher 95% confidence values
obtained in the Table I.
Table I IC50 and IC90 values of various human cell lines and bone marrow cells exposed CDDP
as measured in a clonogenic assay
Cell lines IC50 (AM) 95% CI (gM) ICw (AM) 95% CI(#AM)
Neuroblastoma
IGR-N-835 0.4 (a) 1 (a)
SK-N-AS 0.7 (a) 5 (a)
SK-N-SH 0.8 (a) 7.5 (a)
Mixed culture
IGR-N-835 1.29 1.14- 1.47 4.1 3.5-4.9
Bone marrow
GM-CFC
Linear model 85 75-99 156 142-173
Exponential model 54 49-59 159 145-145
CFU-F
Linear model 383 352-419 707 652-952
Exponential model 351 319-392 1106 1000- 1237
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Figure 1 Remaining number of IGR-N-835 colonies, cultured at
a ratio of 10% with normal human bone marrow cells, after I h
of treatment with various concentrations of CDDP.
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Figure 2 Survival proportion of GM-CFC colonies after I h of
treatment with various concentrations of CDDP.
From these results, two therapeutic indices have been
estimated as the ratio of ICso or IC90 values between normal
haematopoietic progenitor cells and tumour cells (Table I).
Given IC50 and IC0,, the therapeutic indices have been found
to be equal to about 50 and 40, respectively.
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Figure 3 Survival proportion of CFU-F colonies after I h of
treatment with various concentrations of CDDP.
Discussion
Our results show that CDDP could be an efficient purging
agent for NB in ABMT purging conditions. According to the
exponential model, a concentration of 39 EM, i.e. 30-fold ICw
(95% CI) should reduce the number of tumour cells in a
mixture (IGR-N-835 and bone marrow cells) by 109.
Cytological involvement of less than 0.1% may exist in
bone marrow selected for ABMT but remains undetectable
(Bayle et al., 1985). However, in our mixture, we decided on
a ratio of 10% of NB cells so that optimal conditions were
achieved with a sufficient number of cell colonies. Tumour
cell survival was estimated using a clonogenic assay to exp-
lore the possible long-term proliferative capacity of NB cells.
In order to evaluate the differential susceptibility of tumour
cells according to their concentration in bone marrow mix-
tures, we carried out another set of experiments using mix-
tures containing 1% of NB cells and similar results were
obtained (data not shown).
With regard to GM-CFC, three studies have been pub-
lished. Ogawa et al. (1975) pointed out that human cells were
less sensitive to CDDP than murine GM-CFC. The other
two papers studied human tumour cells and human GM-
CFC in the presense of CDDP, but separately (Ajani et al.
1985; Umbach et al., 1985). None of these studies was per-
formed in ABMT routine purging conditions.
High-dose chemotherapy is currently used to eradicate
residual disease in NB patients in complete remission (Hart-
mann et al., 1985). Asta-Z, an active metabolite of cyc-
lophosphamide at 100 yM, is currently used in NB bone
marrow purging. Asta-Z treated marrow, however, induces a
Table II Therapeutic index scale of cisplatinum
Remaining survival cell proportion (p) of
Dose IGR-N-835 GM-CFC CFU-F
(JLM) p (95% CI) p (95% CI) p (95% CI)
15 3 x 10-4 (10-4, 8 x 10-4) 0.86 (0.80-0.89) 0.97 (0.96-0.98)
20 2 x 10-5 (5 x 10-6, 8 x 10-5) 0.82 (0.75-0.87) 0.96 (0.95-0.97)
25 10-6 (3 x 10-7, 8 x 10-6) 0.78 (0.70-0.84) 0.95 (0.94-0.96)
30 10-7 (108, 7 x 10-7) 0.74 (0.65-0.81) 0.94 (0.93-0.95)
35 7 x 10-9 (6 x 10-10,7 x 10-8) 0.71 (0.61-0.78) 0.93 (0.92-0.94)
40 5 x 10-10 (3 x 10-11,6x 10-9) 0.67 (0.57-0.76) 0.92 (0.91-0.93)
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more prolonged delay in recovery from aplasia; almost 4
weeks versus 2.5 without bone marrow purge (Beaujean et
al., 1987). In order to reconstitute the haematopoietic system
after purge in vitro, 108 bone marrow cells per kilogram are
reinjected to the patients. If previously harvested bone mar-
row is contaminated, ABMT procedure cannot be applicable.
Maximal proportion of cytologically measureable occult
tumour cells in the infused bone marrow sample is less than
0.1%. This means that, for a patient of 70kg, about 10'°
bone marrow cells and, possibly, 107 tumour cells are rein-
jected. Our results show that a dose of 39ylM of CDDP is an
adequate purging dose for 10' tumour cells (Table II) while
more than 70% of the GM-CFC and more than 90% of the
CFU-F cells remain alive at this dose.
Furthermore, CDDP has been shown to induce cell
differentiation (Tonini et al., 1986). Whether this agent is
able to induce similar effects on NB cells remains to be
elucidated. If CDDP-induced cell differentiation were to be
established then this, associated with the apparently direct
cytotoxic effect of this agent would provide an extremely
powerful means for ridding the marrow of metastatic cells
with minimal damage to the bone marrow. It would also be
of interest to investigate CDDP toxicity to pluripotential
haematopoeitic cells.
We are indebted to Lorna Saint Ange for reviewing the manuscript
and to Jean Lemerle (Departement de Ndiatrie, Institut Gustave
Roussy) for his interest in this work. Sterile water for media prepara-
tion was Volvic water, generously provided by Volvic Co. (Puy-de-
Dome, France). This work was supported by grants from Institut
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